Atypical cystic fibrosis is a mild form of cystic fibrosis. People with this type of cystic fibrosis can experience symptoms that come and go or that are less severe than those people with classic ...

While gene therapy for cystic fibrosis is still in the research phase, researchers aim to correct the defective gene responsible for the disease. Current research is promising. Cystic fibrosis (CF) is ...

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...

From its first description in 1935 until now, clinical outcomes for patients with cystic fibrosis have undergone a dramatic transformation. While the rare genetic disease was once an early death ...

Current treatments for cystic fibrosis are not suitable for all patients. The lack of treatment options is distressing for people suffering from a rare type of this degenerative and life-threatening ...